InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.26
(
0.40%
)
Bitcoin
57,833.74
(
-3.88%
)
Post# of 2795
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12471
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Monday, 01/30/2017 9:30:27 AM

Monday, January 30, 2017 9:30:27 AM

Post# of 2795
It appears the 20 mg is the minimum dose they should have used in the trial as there were no observed AE's at any dose, and there was a clear benefit as the dose escalated. The target was 24 hours, and they made 17 hours. At the higher 20 mg dose, as the CEO indicated, they probably would have made it. Lots of firms on the call as well.. OCRX still has some data mining they need to do. On to the phase III trial design..
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up